Pay in 4 interest-free payments of $7.11 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Proposed mechanisms of GLP-1RA-induced acute pancreatitis include pancreatic duct gland hyperplasia, pancreatic ductal obstruction leading to proinflammatory reactions, acinar cell hypertrophy, and pancreatic vascular injury.36 Additionally, another mechanism seen with the use of these drugs could be the increased risk of gallbladder or biliary diseases, especially when used in higher doses, for longer periods of time, and for weight loss.37 Previous animal studies suggested a risk of acute pancreatitis after GLP-1RA-based treatment.38 In addition, an initial analysis of the Food and Drug Administration's (FDA) adverse event reporting databases suggested an increased risk for acute pancreatitis with GLP-1RA-based therapy.39 It is important to note that this type of data analysis may not be the ideal method for comparing adverse event rates between medications
Funding This paper was supported by Le Ducq consortium grant 17CVD01 and a Novo Nordisk Foundation GUT-MMM grant
It is now being looked into for possible health benefits
The power of NAD+ Lets start with NAD+, which stands for nicotinamide adenine dinucleotide
